Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ANPEP | P15144 | 1/20 | 0.47 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.47 |
| ▸ | GABRP | O00591 | 2/20 | 0.40 |
| ▸ | GABRD | O14764 | 2/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.40 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19606234 | 0.82 | LMNA (0.39) | SLC6A2SLC6A4BLMSLC6A3MEN1 | |
| SCHEMBL13402574 | 0.81 | ANPEP (0.53) | SLC6A2SLC6A4BLMSLC6A3MEN1 | |
| SCHEMBL18897847 | 0.81 | ANPEP (0.53) | SLC6A2SLC6A4BLMSLC6A3MEN1 | |
| SCHEMBL1970043 | 0.81 | ANPEP (0.53) | SLC6A2SLC6A4BLMSLC6A3MEN1 | |
| SCHEMBL18560520 | 0.81 | ALDH1A1 (0.30) | — | |
| SCHEMBL25452771 | 0.75 | — | — | |
| SCHEMBL9969157 | 0.72 | SLC6A2 (0.47) | SLC6A2SLC6A4BLMSLC6A3MEN1 | |
| SCHEMBL26554829 | 0.72 | SLC6A2 (0.47) | SLC6A2SLC6A4BLMSLC6A3MEN1 | |
| SCHEMBL8804965 | 0.72 | SLC6A2 (0.43) | SLC6A2SLC6A4BLMSLC6A3MEN1 | |
| SCHEMBL6077603 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170044095-A1 | COMPOUNDS FOR THE TREATMENT OF SEIZURES AND OTHER CENTRAL NERVOUS SYSTEM DISORDERS AND CONDITIONS | Ketogen, Inc. (CA) | 2017-02-16 | — | — | US | disclosed |
| US-9481637-B2 | Compounds for the treatment of seizures and other central nervous systems disorders and conditions | Ketogen Inc. (CA) | 2016-11-01 | — | — | US | disclosed |
| US-20150344413-A1 | COMPOUNDS FOR THE TREATMENT OF SEIZURES AND OTHER CENTRAL NERVOUS SYSTEM DISORDERS AND CONDITIONS | Ketogen Inc. (CA) | 2015-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044095-A1 | COMPOUNDS FOR THE TREATMENT OF SEIZURES AND OTHER CENTRAL NERVOUS SYSTEM DISORDERS AND CONDITIONS | PC, PYGB, GLS2 | SLC6A2 1329/4885SLC6A4 1990/4885BLM 4381/4885 |
| US-20150344413-A1 | COMPOUNDS FOR THE TREATMENT OF SEIZURES AND OTHER CENTRAL NERVOUS SYSTEM DISORDERS AND CONDITIONS | PC, PYGB, GLS2 | SLC6A2 1329/4885SLC6A4 1990/4885BLM 4381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.